Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 casirivimab/imdevimab studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 77% 10 37,194 Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 77% 9 27,512 Mortality 77% 5 31,254 Ventilation 0% 1 9,198 ICU admission 48% 1 9,682 Hospitalization 55% 4 18,972 Recovery 36% 4 7,080 Cases 74% 3 3,061 Viral clearance 69% 1 1,505 RCTs 68% 7 19,905 Peer-reviewed 84% 3 19,513 Prophylaxis 93% 3 3,061 Early 68% 5 22,392 Late 69% 2 11,741 Casirivimab/imdevimab for COVID-19 c19regn.com Dec 7, 2021 Favors casiri/imdevimab Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 71% 0.29 [0.17-0.48] hosp./death 18/1,355 62/1,341 Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Webb 98% 0.02 [0.00-0.27] death 0/115 57/5,536 Cooper 77% 0.23 [0.03-1.65] death 1/1,148 33/8,534 Tau​2 = 0.28; I​2 = 47.7% Early treatment 68% 0.32 [0.16-0.67] 21/4,801 156/17,591 68% improvement Horby (RCT) 6% 0.94 [0.86-1.03] death 944/4,839 1,026/4,946 Improvement, RR [CI] Treatment Control McCreary 93% 0.07 [0.01-0.51] death 1/652 29/1,304 Tau​2 = 2.86; I​2 = 84.7% Late treatment 69% 0.31 [0.03-3.87] 945/5,491 1,055/6,250 69% improvement Regeneron (RCT) 94% 0.06 [0.00-1.10] symp. case 0/186 8/223 Improvement, RR [CI] Treatment Control Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Isa (DB RCT) 93% 0.07 [0.01-0.28] symp. case 3/729 13/240 Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 93% 0.07 [0.03-0.21] 3/1,756 27/1,305 93% improvement All studies 77% 0.23 [0.11-0.50] 969/12,048 1,238/25,146 77% improvement 10 casirivimab/imdevimab COVID-19 studies c19regn.com Dec 7, 2021 Tau​2 = 0.91; I​2 = 84.7%; Z = 3.73 Effect extraction pre-specified Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 71% 0.29 [0.17-0.48] hosp./death 18/1,355 62/1,341 Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Webb 98% 0.02 [0.00-0.27] death 0/115 57/5,536 Tau​2 = 0.38; I​2 = 59.8% Early treatment 67% 0.33 [0.14-0.77] 20/3,653 123/9,057 67% improvement Horby (RCT) 6% 0.94 [0.86-1.03] death 944/4,839 1,026/4,946 Improvement, RR [CI] Treatment Control McCreary 93% 0.07 [0.01-0.51] death 1/652 29/1,304 Tau​2 = 2.86; I​2 = 84.7% Late treatment 69% 0.31 [0.03-3.87] 945/5,491 1,055/6,250 69% improvement Regeneron (RCT) 94% 0.06 [0.00-1.10] symp. case 0/186 8/223 Improvement, RR [CI] Treatment Control Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Isa (DB RCT) 93% 0.07 [0.01-0.28] symp. case 3/729 13/240 Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 93% 0.07 [0.03-0.21] 3/1,756 27/1,305 93% improvement All studies 77% 0.23 [0.10-0.52] 968/10,900 1,205/16,612 77% improvement 9 casirivimab/imdevimab COVID-19 studies after exclusions c19regn.com Dec 7, 2021 Tau​2 = 0.93; I​2 = 85.9%; Z = 3.56 Effect extraction pre-specified Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Weinreich (RCT) 50% 0.50 [0.09-2.72] 2/2,091 4/2,089 Improvement, RR [CI] Treatment Control Webb 98% 0.02 [0.00-0.27] 0/115 57/5,536 Cooper 77% 0.23 [0.03-1.65] 1/1,148 33/8,534 Tau​2 = 1.24; I​2 = 52.0% Early treatment 84% 0.16 [0.03-0.95] 3/3,354 94/16,159 84% improvement Horby (RCT) 6% 0.94 [0.86-1.03] 944/4,839 1,026/4,946 Improvement, RR [CI] Treatment Control McCreary 93% 0.07 [0.01-0.51] 1/652 29/1,304 Tau​2 = 2.86; I​2 = 84.7% Late treatment 69% 0.31 [0.03-3.87] 945/5,491 1,055/6,250 69% improvement All studies 77% 0.23 [0.06-0.92] 948/8,845 1,149/22,409 77% improvement 5 casirivimab/imdevimab COVID-19 mortality results c19regn.com Dec 7, 2021 Tau​2 = 1.73; I​2 = 76.5%; Z = 2.07 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Horby (RCT) 0% 1.00 [0.89-1.13] 479/4,556 487/4,642 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 0% 1.00 [0.89-1.13] 479/4,556 487/4,642 0% improvement All studies 0% 1.00 [0.89-1.13] 479/4,556 487/4,642 0% improvement 1 casirivimab/imdevimab COVID-19 mechanical ventilation result c19regn.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.00 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cooper 48% 0.52 [0.23-1.20] 6/1,148 85/8,534 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 48% 0.52 [0.23-1.20] 6/1,148 85/8,534 48% improvement All studies 48% 0.52 [0.23-1.20] 6/1,148 85/8,534 48% improvement 1 casirivimab/imdevimab COVID-19 ICU result c19regn.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.53 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Webb 91% 0.09 [0.01-0.63] hosp. 1/115 538/5,536 Improvement, RR [CI] Treatment Control Cooper 52% 0.48 [0.35-0.64] hosp. 45/1,148 703/8,534 Tau​2 = 0.89; I​2 = 63.6% Early treatment 72% 0.28 [0.06-1.28] 46/1,263 1,241/14,070 72% improvement McCreary 48% 0.52 [0.33-0.82] hosp. 22/652 85/1,304 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 48% 0.52 [0.33-0.82] 22/652 85/1,304 48% improvement Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 92% 0.08 [0.00-1.36] 0/841 6/842 92% improvement All studies 55% 0.45 [0.30-0.66] 68/2,756 1,332/16,216 55% improvement 4 casirivimab/imdevimab COVID-19 hospitalization results c19regn.com Dec 7, 2021 Tau​2 = 0.05; I​2 = 33.1%; Z = 3.96 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 71% 0.29 [0.17-0.48] hosp./death 18/1,355 62/1,341 Improvement, RR [CI] Treatment Control Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Webb 98% 0.02 [0.00-0.27] death 0/115 57/5,536 Cooper 77% 0.23 [0.03-1.65] death 1/1,148 33/8,534 Tau​2 = 0.28; I​2 = 32.0% Early treatment 76% 0.24 [0.10-0.58] 21/4,709 156/17,500 76% improvement Horby (RCT) 6% 0.94 [0.86-1.03] death 944/4,839 1,026/4,946 Improvement, RR [CI] Treatment Control McCreary 93% 0.07 [0.01-0.51] death 1/652 29/1,304 Tau​2 = 2.86; I​2 = 84.7% Late treatment 69% 0.31 [0.03-3.87] 945/5,491 1,055/6,250 69% improvement Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 92% 0.08 [0.00-1.36] 0/841 6/842 92% improvement All studies 75% 0.25 [0.10-0.63] 966/11,041 1,217/24,592 75% improvement 7 casirivimab/imdevimab COVID-19 serious outcomes c19regn.com Dec 7, 2021 Tau​2 = 0.92; I​2 = 84.6%; Z = 2.91 Effect extraction pre-specified Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 1,355 (n) 1,341 (n) Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 1,355 (n) 1,341 (n) Tau​2 = 0.00; I​2 = 0.0% Early treatment 29% 0.71 [0.63-0.81] 0/2,802 0/2,773 29% improvement Regeneron (DB RCT) 62% 0.38 [0.23-0.61] recov. time 753 (n) 752 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 62% 0.38 [0.23-0.61] 0/753 0/752 62% improvement All studies 36% 0.64 [0.52-0.80] 0/3,555 0/3,525 36% improvement 4 casirivimab/imdevimab COVID-19 recovery results c19regn.com Dec 7, 2021 Tau​2 = 0.02; I​2 = 52.2%; Z = 3.96 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 48% 0.52 [0.25-1.07] 10/186 23/223 Improvement, RR [CI] Treatment Control Regeneron (DB RCT) 81% 0.19 [0.12-0.30] 20/841 108/842 Isa (DB RCT) 93% 0.07 [0.01-0.28] 0/729 10/240 Tau​2 = 0.39; I​2 = 68.4% Prophylaxis 74% 0.26 [0.11-0.66] 30/1,756 141/1,305 74% improvement All studies 74% 0.26 [0.11-0.66] 30/1,756 141/1,305 74% improvement 3 casirivimab/imdevimab COVID-19 case results c19regn.com Dec 7, 2021 Tau​2 = 0.39; I​2 = 68.4%; Z = 2.86 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (DB RCT) 69% 0.31 [0.17-0.55] viral time 753 (n) 752 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 69% 0.31 [0.17-0.55] 0/753 0/752 69% improvement All studies 69% 0.31 [0.17-0.55] 0/753 0/752 69% improvement 1 casirivimab/imdevimab COVID-19 viral clearance result c19regn.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.92 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 71% 0.29 [0.17-0.48] hosp./death 18/1,355 62/1,341 Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Tau​2 = 0.07; I​2 = 28.5% Early treatment 60% 0.40 [0.23-0.69] 20/3,538 66/3,521 60% improvement Horby (RCT) 6% 0.94 [0.86-1.03] death 944/4,839 1,026/4,946 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 6% 0.94 [0.86-1.03] 944/4,839 1,026/4,946 6% improvement Regeneron (RCT) 94% 0.06 [0.00-1.10] symp. case 0/186 8/223 Improvement, RR [CI] Treatment Control Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Isa (DB RCT) 93% 0.07 [0.01-0.28] symp. case 3/729 13/240 Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 93% 0.07 [0.03-0.21] 3/1,756 27/1,305 93% improvement All studies 68% 0.32 [0.14-0.72] 967/10,133 1,119/9,772 68% improvement 7 casirivimab/imdevimab COVID-19 Randomized Controlled Trials c19regn.com Dec 7, 2021 Tau​2 = 0.74; I​2 = 86.0%; Z = 2.77 Effect extraction pre-specified Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Weinreich (RCT) 50% 0.50 [0.09-2.72] 2/2,091 4/2,089 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 50% 0.50 [0.09-2.72] 2/2,091 4/2,089 50% improvement Horby (RCT) 6% 0.94 [0.86-1.03] 944/4,839 1,026/4,946 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 6% 0.94 [0.86-1.03] 944/4,839 1,026/4,946 6% improvement All studies 6% 0.94 [0.87-1.02] 946/6,930 1,030/7,035 6% improvement 2 casirivimab/imdevimab COVID-19 RCT mortality results c19regn.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.57 Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Improvement, RR [CI] Treatment Control Webb 98% 0.02 [0.00-0.27] death 0/115 57/5,536 Cooper 77% 0.23 [0.03-1.65] death 1/1,148 33/8,534 Tau​2 = 1.24; I​2 = 52.0% Early treatment 84% 0.16 [0.03-0.95] 3/3,354 94/16,159 84% improvement All studies 84% 0.16 [0.03-0.95] 3/3,354 94/16,159 84% improvement 3 casirivimab/imdevimab COVID-19 peer reviewed trials c19regn.com Dec 7, 2021 Tau​2 = 1.24; I​2 = 52.0%; Z = 2.02 Effect extraction pre-specified Favors casiri/imdevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Regeneron (RCT) 38% 0.62 [0.29-1.33] recov. time 92 (n) 91 (n) Improvement, RR [CI] Treatment Control Regeneron (RCT) 54% 0.46 [0.19-1.13] recov. time 92 (n) 91 (n) Regeneron (RCT) 71% 0.29 [0.17-0.48] hosp./death 18/1,355 62/1,341 Regeneron (RCT) 70% 0.30 [0.13-0.68] hosp./death 7/736 24/748 Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 1,355 (n) 1,341 (n) Regeneron (RCT) 29% 0.71 [0.60-0.85] recov. time 736 (n) 748 (n) Weinreich (RCT) 50% 0.50 [0.09-2.72] death 2/2,091 4/2,089 Weinreich (RCT) 67% 0.33 [0.03-3.17] death 1/1,355 3/1,341 Weinreich (RCT) -2% 1.02 [0.06-16.2] death 1/736 1/748 Weinreich (RCT) 71% 0.29 [0.17-0.48] hosp./death 18/1,355 62/1,341 Weinreich (RCT) 70% 0.30 [0.13-0.68] hosp./death 7/736 24/748 Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 1,355 (n) 1,341 (n) Weinreich (RCT) 29% 0.71 [0.58-0.87] recov. time 736 (n) 748 (n) Webb 98% 0.02 [0.00-0.27] death 0/115 57/5,536 Webb 91% 0.09 [0.01-0.63] hosp. 1/115 538/5,536 Cooper 77% 0.23 [0.03-1.65] death 1/1,148 33/8,534 Cooper 48% 0.52 [0.23-1.20] ICU 6/1,148 85/8,534 Cooper 52% 0.48 [0.35-0.64] hosp. 45/1,148 703/8,534 Horby (RCT) 6% 0.94 [0.86-1.03] death 944/4,839 1,026/4,946 Horby (RCT) 0% 1.00 [0.89-1.13] ventilation 479/4,556 487/4,642 Horby (RCT) 20% 0.80 [0.70-0.91] death 396/1,633 451/1,520 Horby (RCT) 12% 0.88 [0.73-1.06] ventilation 189/1,599 200/1,484 McCreary 93% 0.07 [0.01-0.51] death 1/652 29/1,304 McCreary 56% 0.44 [0.28-0.68] hosp./death 22/652 101/1,304 McCreary 48% 0.52 [0.33-0.82] hosp. 22/652 85/1,304 McCreary 40% 0.60 [0.43-0.85] hosp./ER 40/652 133/1,304 Regeneron (RCT) 94% 0.06 [0.00-1.10] symp. case 0/186 8/223 Regeneron (RCT) 48% 0.52 [0.25-1.07] cases 10/186 23/223 Regeneron (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/841 6/842 Regeneron (DB RCT) 81% 0.19 [0.12-0.30] cases 20/841 108/842 Regeneron (DB RCT) 82% 0.18 [0.08-0.41] cases 7/841 38/842 Regeneron (DB RCT) 89% 0.11 [0.01-2.06] hosp./ER 0/753 4/752 Regeneron (DB RCT) 81% 0.19 [0.10-0.35] symp. case 11/753 59/752 Regeneron (DB RCT) 62% 0.38 [0.23-0.61] recov. time 753 (n) 752 (n) Regeneron (DB RCT) 69% 0.31 [0.17-0.55] viral time 753 (n) 752 (n) Isa (DB RCT) 93% 0.07 [0.01-0.28] symp. case 3/729 13/240 Isa (DB RCT) 93% 0.07 [0.01-0.28] cases 0/729 10/240 casirivimab/imdevimab COVID-19 outcomes c19regn.com Dec 7, 2021 Favors casiri/imdevimab Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit